Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab

Abstract

Background: The emergence of new biological therapies showing high and sustained level of Psoriasis Area and Severity Index (PASI) 90 response has provided the possibility of both greater skin clearance and increased quality of life (QOL).

Objective: To evaluate the association of greater response in skin clearance with improvements in skin-related QOL up to 52 weeks.

Methods: Subjects achieving various levels of skin clearance (PASI 90–100 or PASI 75–89) and Dermatology Life Quality Index (DLQI) (0/1) response were compared using ERASURE and FIXTURE trial data. Similar analyses with IGA ratings of Clear or Almost Clear were performed.

Results: Significantly more PASI 90–100 responders at week 12 had DLQI 0/1 response than PASI 75–89 (69.4% vs. 47.1%; p < .001) and sustained DLQI 0/1 response at week 52 (74.0% vs. 56.7%; p < .001). IGA results were similar.

Conclusions: These results show that PASI 90–100 is a relevant therapeutic goal in moderate to severe psoriasis compared to PASI 75–89 when considering patients’ QOL.

Keywords:

• Psoriasis
• secukinumab
• patient-reported outcome
• DLQI
• PASI
• IGA

View correction statement:

Correction to: Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab

Acknowledgements

The authors would like to thank the patients and the investigators who participated in the studies; Lori McLeod, PhD and Nicole Williams, BS, for reviewing the manuscript; and S. Daniel Siepert, MA, for medical editorial assistance with this manuscript.

Disclosure statement

Dr. Elewski has served as a consultant for Amgen, Abbott, Merck, Novartis, Pfizer, Eli Lilly, and Novartis and receives grant support through the University of Alabama Birmingham from Janssen, Amgen, Lilly, Pfizer, and Merck. Dr. Puig has served as a consultant for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly, Gebro, Janssen, LEO Pharma, Merck (MSD), Merck-Serono, Novartis, Pfizer, Regeneron, Roche and Sandoz and as an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Merck (MSD), Novartis, Pfizer, Regeneron and Roche. Ms. Mordin is a full-time employee of RTI Health Solutions. Ms. Gilloteau is a full-time employee of Novartis. Ms. Sherif is a full-time employee of RTI Health Solutions. Dr. Fox is a full-time employee of Novartis. Mr. Gnanasakthy was a full-time employee of Novartis and is currently a full-time employee of RTI Health Solutions. Dr. Papavassilis is a full-time employee of Novartis. Dr. Strober has served as part of the Speakers? Bureau for AbbVie; as a consultant for AbbVie, Amgen, Celgene, Dermira, Janssen, Leo, Eli Lilly, Maruho, Medac, Merck, Novartis, Pfizer, Stiefel/GlaxoSmithKline, UCB; as an investigator for AbbVie, Amgen, Novartis, Eli Lilly, Janssen, and Merck; and as a scientific director for CORRONA Psoriasis Registry. Dr. Strober also receives grant support through the University of Connecticut from AbbVie and Janssen.

Additional information

Funding

This work was supported by the Novartis Pharmaceuticals Corporation.